Upfront Payments. Prior to the commencement of any GLP toxicity study for the first Licensed Product by Genocea, its Affiliates or a Sublicensee in each of the Non-Exclusive Disease Fields, Genocea shall pay to Isconova an upfront, non-creditable, non-refundable fee of [* * *]. For the avoidance of doubt, payments under this Section 6.2 shall only be payable by Genocea once for each unique Disease Field, irrespective of the number of Licensed Products in any given Disease Field that become the subject of a GLP toxicity study.
Appears in 4 contracts
Sources: License and Collaboration Agreement (Genocea Biosciences, Inc.), License and Collaboration Agreement (Genocea Biosciences, Inc.), License and Collaboration Agreement (Genocea Biosciences, Inc.)